These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

204 related articles for article (PubMed ID: 25046796)

  • 1. The effect of hypogonadism and testosterone-enhancing therapy on alkaline phosphatase and bone mineral density.
    Dabaja AA; Bryson CF; Schlegel PN; Paduch DA
    BJU Int; 2015 Mar; 115(3):480-5. PubMed ID: 25046796
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Increase in bone density and lean body mass during testosterone administration in men with acquired hypogonadism.
    Katznelson L; Finkelstein JS; Schoenfeld DA; Rosenthal DI; Anderson EJ; Klibanski A
    J Clin Endocrinol Metab; 1996 Dec; 81(12):4358-65. PubMed ID: 8954042
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bone mineral density in hypogonadal men remains low after long-term testosterone replacement.
    Ishizaka K; Suzuki M; Kageyama Y; Kihara K; Yoshida K
    Asian J Androl; 2002 Jun; 4(2):117-21. PubMed ID: 12085102
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of testosterone replacement in hypogonadal men.
    Snyder PJ; Peachey H; Berlin JA; Hannoush P; Haddad G; Dlewati A; Santanna J; Loh L; Lenrow DA; Holmes JH; Kapoor SC; Atkinson LE; Strom BL
    J Clin Endocrinol Metab; 2000 Aug; 85(8):2670-7. PubMed ID: 10946864
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Changes in prostate specific antigen in hypogonadal men after 12 months of testosterone replacement therapy: support for the prostate saturation theory.
    Khera M; Bhattacharya RK; Blick G; Kushner H; Nguyen D; Miner MM
    J Urol; 2011 Sep; 186(3):1005-11. PubMed ID: 21788049
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment of isolated hypogonadotropic hypogonadism effect on bone mineral density and bone turnover.
    Guo CY; Jones TH; Eastell R
    J Clin Endocrinol Metab; 1997 Feb; 82(2):658-65. PubMed ID: 9024272
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Effect of immunosuppression-induced hypogonadism on bone metabolism after heart transplantation].
    Stief J; Sohn HY; Alt A; Uberfuhr P; Theisen K; Stempfle HU
    Dtsch Med Wochenschr; 2004 Jul; 129(31-32):1674-8. PubMed ID: 15273918
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of long-acting testosterone undecanoate on bone mineral density in middle-aged men with late-onset hypogonadism and metabolic syndrome: results from a 36 months controlled study.
    Aversa A; Bruzziches R; Francomano D; Greco EA; Fornari R; Di Luigi L; Lenzi A; Migliaccio S
    Aging Male; 2012 Jun; 15(2):96-102. PubMed ID: 22439807
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Testosterone replacement in congenital hypogonadotropic hypogonadism maintains bone density but has only limited osteoanabolic effects.
    Antonio L; Caerels S; Jardi F; Delaunay E; Vanderschueren D
    Andrology; 2019 May; 7(3):302-306. PubMed ID: 30851011
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Optimal diagnostic measures and thresholds for hypogonadism in men with HIV/AIDS: comparison between 2 transdermal testosterone replacement therapy gels.
    Blick G
    Postgrad Med; 2013 Mar; 125(2):30-9. PubMed ID: 23816769
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Adequacy of androgen replacement influences bone density response to testosterone in androgen-deficient men.
    Aminorroaya A; Kelleher S; Conway AJ; Ly LP; Handelsman DJ
    Eur J Endocrinol; 2005 Jun; 152(6):881-6. PubMed ID: 15941928
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Testosterone Therapy Effects on Bone Mass and Turnover in Hypogonadal Men with Type 2 Diabetes.
    Colleluori G; Aguirre L; Napoli N; Qualls C; Villareal DT; Armamento-Villareal R
    J Clin Endocrinol Metab; 2021 Jul; 106(8):e3058-e3068. PubMed ID: 33735389
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-term effect of testosterone therapy on bone mineral density in hypogonadal men.
    Behre HM; Kliesch S; Leifke E; Link TM; Nieschlag E
    J Clin Endocrinol Metab; 1997 Aug; 82(8):2386-90. PubMed ID: 9253305
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy of changing testosterone gel preparations (Androgel or Testim) among suboptimally responsive hypogonadal men.
    Grober ED; Khera M; Soni SD; Espinoza MG; Lipshultz LI
    Int J Impot Res; 2008; 20(2):213-7. PubMed ID: 17898800
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of transdermal testosterone gel on bone turnover markers and bone mineral density in hypogonadal men.
    Wang C; Swerdloff RS; Iranmanesh A; Dobs A; Snyder PJ; Cunningham G; Matsumoto AM; Weber T; Berman N
    Clin Endocrinol (Oxf); 2001 Jun; 54(6):739-50. PubMed ID: 11422108
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Serum adiponectin levels in hypogonadal males: influence of testosterone replacement therapy.
    Lanfranco F; Zitzmann M; Simoni M; Nieschlag E
    Clin Endocrinol (Oxf); 2004 Apr; 60(4):500-7. PubMed ID: 15049966
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of testosterone replacement therapy on cortical and trabecular bone mineral density, vertebral body area and paraspinal muscle area in hypogonadal men.
    Leifke E; Körner HC; Link TM; Behre HM; Peters PE; Nieschlag E
    Eur J Endocrinol; 1998 Jan; 138(1):51-8. PubMed ID: 9461316
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of long-term testosterone substitutive therapy on bone mineral content in men with hypergonadotrophic hypogonadism.
    Medras M; Jankowska EA; Rogucka E
    Andrologia; 2001 Jan; 33(1):47-52. PubMed ID: 11167519
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bone mineral density outcomes following long-term treatment with subcutaneous testosterone pellet implants in male hypogonadism.
    Zacharin MR; Pua J; Kanumakala S
    Clin Endocrinol (Oxf); 2003 Jun; 58(6):691-5. PubMed ID: 12780744
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Correlation between simultaneous PSA and serum testosterone concentrations among eugonadal, untreated hypogonadal and hypogonadal men receiving testosterone replacement therapy.
    Grober ED; Lamb DJ; Khera M; Murthy L; Lipshultz LI
    Int J Impot Res; 2008; 20(6):561-5. PubMed ID: 18843272
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.